Skip to main content

Table 1 Baseline clinical information of the investigated glioma patients

From: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Variable Number of cases
Gender
 Male 14
 Female 16
WHO grade
 I–II 10
 III 10
 IV 10
Age (years)
 < 40 7
 40–49 10
 50–59 9
 60–69 2
 ≥ 70 2
Resection type
 Total 24
 Partial 6
 Survival status
 Alive 17
 Dead 13
Pathologic diagnosis
 Astrocytoma 7
 Oligodendroglioma/oligoastrocytoma 3
 Anaplastic astrocytoma 5
 Anaplastic oligodendroglioma/mixed 5
 Glioblastoma 10
  1. WHO World Health Organization